follow us:Google+ FacebookLinkedInTwitterRSS Feeds

advertisement

Soligenix gets orphan drug designation for radiation treatment

By

Back to Top Comments Print

News You Can Use

Latest News

advertisement

Princeton-based pharmaceutical company Soligenix announced today the Food and Drug Administration has granted it orphan drug designation for its acute radiation syndrome treatment, SGX94. The Office of Orphan Products Development granted the designation.

According to the announcement, in addition to providing a seven-year term of market exclusivity upon final FDA approval, orphan drug designation also positions Soligenix to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees for the potential submission of a New Drug Application, and certain tax credits.

Write to the Editorial Department at editorial@njbiz.com

advertisement

Advanced search
Sponsored by
advertisement
  
  
advertisement
  
  
advertisement
Back to Top